Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 76,084 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 76,084 shares of the company's stock, valued at approximately $4,259,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.12% of Rhythm Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in RYTM. SRS Capital Advisors Inc. lifted its position in shares of Rhythm Pharmaceuticals by 740.7% in the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock worth $25,000 after buying an additional 400 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in Rhythm Pharmaceuticals in the 4th quarter worth approximately $37,000. R Squared Ltd bought a new stake in Rhythm Pharmaceuticals during the fourth quarter worth approximately $44,000. State of Wyoming acquired a new position in Rhythm Pharmaceuticals during the fourth quarter valued at approximately $61,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Rhythm Pharmaceuticals in the fourth quarter valued at approximately $72,000.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on RYTM. Wells Fargo & Company raised their target price on shares of Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the company an "overweight" rating in a research note on Monday, April 7th. Morgan Stanley reaffirmed an "overweight" rating and set a $72.00 price objective on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a research note on Tuesday, April 8th. Canaccord Genuity Group boosted their price target on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. Finally, Needham & Company LLC raised their price objective on shares of Rhythm Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday, May 7th. Thirteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Rhythm Pharmaceuticals currently has an average rating of "Buy" and an average target price of $76.62.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, EVP Yann Mazabraud sold 6,745 shares of the company's stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $65.08, for a total transaction of $438,964.60. Following the sale, the executive vice president now owns 37,655 shares of the company's stock, valued at approximately $2,450,587.40. This represents a 15.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Pamela J. Cramer sold 20,760 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, April 8th. The stock was sold at an average price of $60.14, for a total value of $1,248,506.40. Following the completion of the sale, the insider now owns 19,209 shares of the company's stock, valued at approximately $1,155,229.26. The trade was a 51.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 127,630 shares of company stock worth $7,107,346 in the last ninety days. Company insiders own 6.10% of the company's stock.

Rhythm Pharmaceuticals Stock Performance

Rhythm Pharmaceuticals stock traded up $2.01 during trading hours on Tuesday, reaching $65.67. 757,157 shares of the company's stock traded hands, compared to its average volume of 555,995. The firm's 50 day moving average is $59.74 and its 200-day moving average is $57.59. The firm has a market capitalization of $4.18 billion, a price-to-earnings ratio of -15.17 and a beta of 2.36. Rhythm Pharmaceuticals, Inc. has a fifty-two week low of $36.27 and a fifty-two week high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The business had revenue of $37.72 million during the quarter, compared to analyst estimates of $40.43 million. During the same quarter last year, the business earned ($2.35) earnings per share. Rhythm Pharmaceuticals's revenue for the quarter was up 25.9% on a year-over-year basis. Analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current year.

Rhythm Pharmaceuticals Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.